{"id":985272,"date":"2026-07-27T18:00:04","date_gmt":"2026-07-27T22:00:04","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/genedx-holdings-corp-nasdaq-wgs-investors-who-suffered-losses-may-be-eligible-to-participate-in-securities-class-action\/"},"modified":"2026-07-27T18:00:04","modified_gmt":"2026-07-27T22:00:04","slug":"genedx-holdings-corp-nasdaq-wgs-investors-who-suffered-losses-may-be-eligible-to-participate-in-securities-class-action","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/genedx-holdings-corp-nasdaq-wgs-investors-who-suffered-losses-may-be-eligible-to-participate-in-securities-class-action\/","title":{"rendered":"GeneDx Holdings Corp. (NASDAQ: WGS) Investors Who Suffered Losses May Be Eligible to Participate in Securities Class Action"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n Lead Plaintiff Deadline: August 3, 2026<\/b>\n <\/p>\n

\n SAN DIEGO<\/span>, July 27, 2026<\/span> \/PRNewswire\/ — Robbins LLP<\/a>\u00a0reminds investors that a securities class action has been filed on behalf of all persons and entities who purchased or otherwise acquired GeneDx Holdings Corp. (NASDAQ: WGS) common stock between April 16, 2025 and May 4, 2026, inclusive (the “Class Period”).<\/p>\n

\n

\n \"Robbins\n <\/p>\n<\/p><\/div>\n

The lawsuit alleges<\/span><\/span> that GeneDx Holdings Corp. misled investors about the expected benefits and financial impact of its acquisition of Fabric Genomics, an AI-driven genomic interpretation company.<\/p>\n

Investors who suffered losses during the Class Period may have legal rights and should be aware of the August 3, 2026<\/b>\u00a0deadline to seek appointment as lead plaintiff.<\/p>\n

\n Why Was GeneDx Sued?<\/b>\n <\/p>\n

According to the complaint, GeneDx announced in April 2025 that it would acquire Fabric Genomics in a transaction valued at up to $51 million. GeneDx represented that the acquisition would expand its addressable market, create multiple scalable revenue streams, and transform genomic data into a recurring revenue-generating platform.<\/p>\n

After the acquisition closed, GeneDx continued to represent that Fabric’s interpretation-as-a-service model would create recurring software-based revenue streams and generate efficiencies with GeneDx’s existing business.<\/p>\n

The complaint alleges<\/span><\/span> that these statements led investors to believe that the Fabric acquisition would improve GeneDx’s financial performance and create meaningful strategic and operational benefits. According to the lawsuit, however, defendants allegedly<\/span><\/span> knew, or recklessly disregarded, significant problems concerning Fabric’s viability that would negatively affect GeneDx’s business and operations.<\/p>\n

The complaint alleges<\/span><\/span> that GeneDx’s public statements concerning the acquisition and its expected benefits were therefore materially false or misleading.<\/p>\n

\n What Happened to GeneDx Stock?<\/b>\n <\/p>\n

The complaint alleges<\/span><\/span> that the truth concerning Fabric Genomics and GeneDx’s financial outlook emerged on May 4, 2026, when GeneDx reported its first-quarter 2026 financial results.<\/p>\n

GeneDx disclosed that it had missed revenue estimates for both its exome and genome testing lines.<\/p>\n

The Company also significantly reduced its full-year 2026 revenue guidance:<\/p>\n